Daytrana (methylphenidate transdermal system) / Hisamitsu - LARVOL DELTA

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

NCI-2018-02527: Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer (clinicaltrials.gov) - P2/3 | N=200 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Case Report of Orofacial Dyskinesia With Transdermal Methylphenidate. (PubMed, J Dev Behav Pediatr) - "To inform medication management for ADHD in children with comorbidities, it is valuable to define specific risk factors for adverse effects and intolerability of medication. Identifying if patient age, weight, comorbidities, previous antipsychotic or stimulant use, and concurrent medication use are demonstrable risk factors for dyskinesia can help practitioners develop a more individualized medication treatment plan for children with ADHD."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Constipation • Depression • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Insomnia • Mental Retardation • Mood Disorders • Movement Disorders • Pediatrics • Psychiatry • Sleep Disorder

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: Matthew J O'Brien, PhD, BCBA-D | Trial completion date: Jan 2025 ➔ Aug 2027 | Trial primary completion date: Jan 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

NCI-2018-00698: Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy (clinicaltrials.gov) - P3 | N=212 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Metastases • Trial completion date • Trial primary completion date • Fatigue • Oncology • CXCL8 • IL10 • IL1B • IL1R1 • IL6 • TNFA

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4 | N=226 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Mar 2028 ➔ Sep 2027 | Trial primary completion date: Jun 2027 ➔ Sep 2027

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Epilepsy

NCI-2018-02527: Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer (clinicaltrials.gov) - P2/3 | N=200 | Recruiting | Sponsor: M.D. Anderson Cancer Center | N=354 ➔ 200 | Trial completion date: Nov 2023 ➔ Nov 2026 | Trial primary completion date: Nov 2023 ➔ Nov 2026

Combination therapy • Enrollment change • Trial completion date • Trial primary completion date • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CRP

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4 | N=226 | Recruiting | Sponsor: VA Office of Research and Development | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Cognitive Disorders • Epilepsy

"These include brand name (= Generic version): - @VYVANSE (Lisdexamfetamine) - Concerta, Ritalin LA, Daytrana, etc (Methylphenidate) - Focalin ER (Dexmethylphenidate ER) @Novartis - Adderall XR - Dexedrine, etc (Dextroamphetamine) - Azstarys These last 12 hours or longer" (@RTorof)

NCI-2018-00698: Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy (clinicaltrials.gov) - P3 | N=212 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Fatigue • Oncology

Transdermal dextroamphetamine (Xelstrym) for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4 | N=226 | Not yet recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Dec 2027 ➔ Mar 2028 | Trial primary completion date: Dec 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Epilepsy

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4 | N=226 | Not yet recruiting | Sponsor: VA Office of Research and Development | N=77 ➔ 226 | Trial completion date: Mar 2027 ➔ Dec 2027 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Epilepsy

Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy (clinicaltrials.gov) - P3; N=212; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Active, not recruiting; N=398 ➔ 212; Trial completion date: Jun 2021 ➔ Dec 2022; Trial primary completion date: Jun 2021 ➔ Dec 2022

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Fatigue • Oncology

Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Prescription stimulant brand name recognition among a national sample of 10- to 18-year-old youth. (PubMed, Int J Methods Psychiatr Res) - "These results provide strong evidence of the need for more stringent methods for youth to report drug use."

Journal

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Matthew J O'Brien, PhD, BCBA-D; Trial completion date: Jan 2021 ➔ Jan 2025; Trial primary completion date: Jan 2021 ➔ Jan 2025

Clinical • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (clinicaltrials.gov) - P4; N=77; Not yet recruiting; Sponsor: VA New York Harbor Healthcare System

Clinical • New P4 trial • Alzheimer's Disease • CNS Disorders • Epilepsy • Solid Tumor

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P=N/A; N=10; Not yet recruiting; Sponsor: Matthew O'Brien

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Biosimilar • CNS Disorders

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review

Jornay PM -- evening-dosed methylphenidate for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal

Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy (clinicaltrials.gov) - P3; N=398; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Nov 2019 ➔ Jun 2021; Trial primary completion date: Nov 2019 ➔ Jun 2021

Clinical • PD(L)-1 Biomarker • Trial completion date • Trial primary completion date

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Matthew J O'Brien, PhD, BCBA-D; Trial completion date: Jan 2019 ➔ Jan 2021; Trial primary completion date: Jan 2019 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer (clinicaltrials.gov) - P2/3; N=354; Recruiting; Sponsor: M.D. Anderson Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open

Methylphenidate and Physical Activity in Reducing Cancer-Related Fatigue in Participants With Metastatic Melanoma Who Receive Anti-PD1 Immunotherapy (clinicaltrials.gov) - P3; N=398; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Nov 2018 ➔ Nov 2019; Trial primary completion date: Nov 2018 ➔ Nov 2019

Clinical • PD(L)-1 Biomarker • Trial completion date • Trial primary completion date